Tefibazumab: Difference between revisions

Tefibazumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	Clumping factor A
Clinical data
Trade names	Aurexis
ATC code	none;
Identifiers
CAS Number	521079-87-8 ;
ChemSpider	none;
UNII	SBO7Q9G95R;
KEGG	D06054 ;
Chemical and physical data
Formula	C6548H10122N1730O2034S44
Molar mass	147035.72 g·mol−1
	(what is this?) (verify)

Browse history interactively

← Previous edit

Content deleted Content added

VisualWikitext

Inline

Latest revision as of 20:57, 1 December 2023

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis^[1] and of methicillin-resistant S. aureus.^[2]

It was developed by Inhibitex.^[3]

References

^ Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
^ Pan A, Lorenzotti S, Zoncada A (January 2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-Infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
^ John JF (October 2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Current Opinion in Molecular Therapeutics. 8 (5): 455–60. PMID 17078388.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

[1] Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov

[2] Pan A, Lorenzotti S, Zoncada A (January 2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-Infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.

[pmid17078388-3] John JF (October 2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Current Opinion in Molecular Therapeutics. 8 (5): 455–60. PMID 17078388.

[1]

[2]

[3]

@@ Line 1: / Line 1: @@
+{{Short description|Monoclonal antibody}}
 {{Drugbox
 | Verifiedfields = changed
+| Watchedfields = changed
 | verifiedrevid = 470478505
 | image =
+<!-- Monoclonal antibody data -->
-<!--Monoclonal antibody data-->
 | type = mab
 | mab_type = mab
 | source = zu/o
 | target = [[Clumping factor A]]
+<!-- Clinical data -->
+| tradename = Aurexis
-<!--Clinical data-->
-| tradename =
 | pregnancy_AU =
 | pregnancy_US =
@@ Line 21: / Line 21: @@
 | legal_status =
 | routes_of_administration =
+<!-- Pharmacokinetic data -->
-<!--Pharmacokinetic data-->
 | bioavailability =
 | protein_bound =
@@ Line 28: / Line 27: @@
 | elimination_half-life =
 | excretion =
+<!-- Identifiers -->
+| CAS_number_Ref = {{cascite|changed|CAS}}
-<!--Identifiers-->
-| CAS_number_Ref = {{cascite|changed|??}}
 | CAS_number = 521079-87-8
+| UNII_Ref = {{fdacite|changed|FDA}}
+| UNII = SBO7Q9G95R
 | ATC_prefix = none
 | ATC_suffix =
@@ Line 39: / Line 39: @@
 | KEGG_Ref = {{keggcite|correct|kegg}}
 | KEGG = D06054
-| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
-| ChemSpiderID = NA
+| ChemSpiderID = none
+<!-- Chemical data -->
+| C=6548 | H=10122 | N=1730 | O=2034 | S=44
-<!--Chemical data-->
-| C=6548 | H=10122 | N=1730 | O=2034 | S=44
-| molecular_weight = 147.590 [[kDa]]
 }}
-'''Tefibazumab''' (marketed under the brand name '''Aurexis''') is a [[humanized monoclonal antibody]] for the treatment of severe infections with ''[[Staphylococcus aureus]]''. Possible indications include the treatment of ''S. aureus'' in patient with [[cystic fibrosis]]<ref>{{ClinicalTrialsGov|NCT00198289}}</ref> and of [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''S. aureus'']].<ref>{{pmid|18221183}}</ref>
+'''Tefibazumab''' (named '''Aurexis''' but not approved) is a [[humanized monoclonal antibody]] for the treatment of severe infections with ''[[Staphylococcus aureus]]''. Possible indications include the treatment of ''S. aureus'' in a phase 2a patients with [[cystic fibrosis]]<ref>{{ClinicalTrialsGov|NCT00198289|Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs}}</ref> and of [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''S. aureus'']].<ref>{{cite journal | vauthors = Pan A, Lorenzotti S, Zoncada A | title = Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection | journal = Recent Patents on Anti-Infective Drug Discovery | volume = 3 | issue = 1 | pages = 10–33 | date = January 2008 | pmid = 18221183 | doi = 10.2174/157489108783413173 }}</ref>
-It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal |author=John JF |title=Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection |journal=Curr. Opin. Mol. Ther. |volume=8 |issue=5 |pages=455–60 |year=2006 |pmid=17078388 |doi=}}</ref>
+It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal | vauthors = John JF | title = Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection | journal = Current Opinion in Molecular Therapeutics | volume = 8 | issue = 5 | pages = 455–60 | date = October 2006 | pmid = 17078388 }}</ref>
-==See also==
+== See also ==
 * [[MSCRAMM]] (microbial surface components recognizing adhesive matrix molecules)
-==References==
+== References ==
 {{reflist}}
@@ Line 60: / Line 58: @@
 [[Category:Monoclonal antibodies]]
+[[Category:Experimental monoclonal antibodies]]
 {{antiinfective-drug-stub}}
 {{monoclonal-antibody-stub}}